Becton Dickinson to acquire Bard for $24bn

Medical technology company Becton Dickinson (BD) will acquire C R Bard, a business in the same industry, for $24 billion.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Pharma

Novo’s semaglutide protection weakens after European ruling

13 October 2026 Generic challengers have scored a win against the Danish company after an appeals board revoked a key patent covering the cardiovascular use of semaglutide. The decision strips away another layer of protection as generic manufacturers hunt down the semaglutide franchise.

MedTech

Boston Scientific expands dispute with J&J unit over cardiac-access technology

12 October 2026 The two major medical device makers are clashing over Atraverse’s Hotwire system, with Boston Scientific claiming the product infringes its patented radiofrequency transseptal-access technology, used in heart surgery.

Careers

Brazilian firm appoints patent strategist to lead department

12 October 2026 Ouro Preto Paranhos has brought in a licensed pharmacist with more than 26 years of intellectual property experience to lead the patent practice at the Rio de Janeiro firm.

More features

Novo’s semaglutide protection weakens after European ruling

UK to clamp down on non-compete clauses and long notice periods

Boston Scientific expands dispute with J&J unit over cardiac-access technology

Brazilian firm appoints patent strategist to lead department

AIPPI World Congress: ‘Diversity need not be an obstacle to unity’

Novartis pursues Apotex over copies of $2bn skin cancer drug franchise

MSD’s Keytruda hit by eight-country ban across Europe

Foley Hoag adds two partners in Denver expansion

Becton Dickinson to acquire Bard for $24bn

More on this story

Editor's picks

Editor's picks

More features